ViiV Healthcare
| Company type | Joint venture |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 2009 |
| Headquarters | London, England, UK |
Area served | Worldwide |
Key people | Deborah Waterhouse (CEO) |
| Products | Pharmaceuticals |
| Owners | |
Number of employees | c. 1,100 (2023) |
| Website | viivhealthcare |
ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.
ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.
ViiV Healthcare's global headquarters are in London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.